Sodium Channel Blockers for Vestibular Paroxysmia in Children.

IF 2.1 Q1 AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY
Pierre Reynard, Hung Thai-Van, Eugenia Mustea, Alexandra Neagu, Samar A Idriss, Eugen C Ionescu
{"title":"Sodium Channel Blockers for Vestibular Paroxysmia in Children.","authors":"Pierre Reynard, Hung Thai-Van, Eugenia Mustea, Alexandra Neagu, Samar A Idriss, Eugen C Ionescu","doi":"10.3390/audiolres15030065","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> As vestibular paroxysmia (VP) has recently been described in children, with an incidence of up to 4% of vertigo, and a promising therapeutic response to sodium-channel-blocking drugs has also been reported, the aim of this paper is to review the available literature on this topic and to provide the best possible guidance for diagnosis and treatment. <b>Methods</b>: PubMed, Medline, Cochrane, and Crossref databases were searched, and all studies on VP in children and sodium channel blockers were selected. <b>Results</b>: Only five articles reporting small case series or single case reports were identified. To date, oxcarbazepine (OXC) and carbamazepine (CBZ) are the only two molecules prescribed. The recommended doses were 300 to 360 mg/day and 50 to 200 mg/day for OXC and CBZ, respectively, for a total duration of 6 weeks. Fast efficacy (one week) was reported. <b>Conclusions</b>: VP has been identified in pediatric patients and appears to respond to sodium channel blockers in a manner similar to adults. Only a limited number of cases have been reported to date; thus, there is a need to raise awareness about this treatable cause of episodic vertigo in children.</p>","PeriodicalId":44133,"journal":{"name":"Audiology Research","volume":"15 3","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189259/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Audiology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/audiolres15030065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: As vestibular paroxysmia (VP) has recently been described in children, with an incidence of up to 4% of vertigo, and a promising therapeutic response to sodium-channel-blocking drugs has also been reported, the aim of this paper is to review the available literature on this topic and to provide the best possible guidance for diagnosis and treatment. Methods: PubMed, Medline, Cochrane, and Crossref databases were searched, and all studies on VP in children and sodium channel blockers were selected. Results: Only five articles reporting small case series or single case reports were identified. To date, oxcarbazepine (OXC) and carbamazepine (CBZ) are the only two molecules prescribed. The recommended doses were 300 to 360 mg/day and 50 to 200 mg/day for OXC and CBZ, respectively, for a total duration of 6 weeks. Fast efficacy (one week) was reported. Conclusions: VP has been identified in pediatric patients and appears to respond to sodium channel blockers in a manner similar to adults. Only a limited number of cases have been reported to date; thus, there is a need to raise awareness about this treatable cause of episodic vertigo in children.

钠通道阻滞剂治疗儿童前庭阵发性发作。
背景/目的:由于前庭阵发性发作(VP)最近在儿童中被描述,其发病率高达眩晕的4%,并且对钠通道阻断药物的治疗反应也有报道,本文的目的是回顾有关该主题的现有文献,并为诊断和治疗提供最好的指导。方法:检索PubMed、Medline、Cochrane和Crossref数据库,选择所有关于儿童VP和钠通道阻滞剂的研究。结果:只有5篇报道小病例系列或单个病例报告的文章被确定。迄今为止,奥卡西平(OXC)和卡马西平(CBZ)是仅有的两种分子。OXC和CBZ的推荐剂量分别为300至360毫克/天和50至200毫克/天,总持续时间为6周。见效快(1周)。结论:小儿患者中已发现副溶血性静脉曲张,并且对钠通道阻滞剂的反应与成人相似。迄今为止,仅报告了数量有限的病例;因此,有必要提高对儿童发作性眩晕的可治疗原因的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Audiology Research
Audiology Research AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY-
CiteScore
2.30
自引率
23.50%
发文量
56
审稿时长
11 weeks
期刊介绍: The mission of Audiology Research is to publish contemporary, ethical, clinically relevant scientific researches related to the basic science and clinical aspects of the auditory and vestibular system and diseases of the ear that can be used by clinicians, scientists and specialists to improve understanding and treatment of patients with audiological and neurotological disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信